APO-TAPENTADOL 50 MG
TAPENTADOL (TAPENTADOL HYDROCHLORIDE) : 50 MG · DIN 02471965 · APOTEX INC
Health Canada status: APPROVED
What is APO-TAPENTADOL?
APO-TAPENTADOL 50 MG contains TAPENTADOL (TAPENTADOL HYDROCHLORIDE) : 50 MG. It is listed in the Health Canada Drug Product Database under DIN 02471965, held by APOTEX INC, supplied as TABLET (IMMEDIATE RELEASE) for ORAL administration. Health Canada currently lists it as approved, status dated 17-Feb-2022. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 02471965 |
|---|---|
| Brand name | APO-TAPENTADOL |
| Generic / active ingredient | TAPENTADOL (TAPENTADOL HYDROCHLORIDE) : 50 MG |
| Manufacturer | APOTEX INC |
| Strength | 50 MG |
| Dosage form | TABLET (IMMEDIATE RELEASE) |
| Route of administration | ORAL |
| Schedule | NARCOTICS (CDSA I) |
| ATC code | N02AX06 TAPENTADOL |
| AHFS class | 28:08.08 |
| Biosimilar | No |
| Health Canada status | APPROVED |
| Status date | 17-Feb-2022 |
What can be used instead?
Other Canadian products sharing ATC code N02AX06 TAPENTADOL. 8 of 16 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| NUCYNTA EXTENDED-RELEASE | 100 MG | TABLET (EXTENDED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02415585 |
| NUCYNTA EXTENDED-RELEASE | 150 MG | TABLET (EXTENDED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02415593 |
| NUCYNTA EXTENDED-RELEASE | 200 MG | TABLET (EXTENDED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02415607 |
| NUCYNTA EXTENDED-RELEASE | 250 MG | TABLET (EXTENDED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02415615 |
| NUCYNTA EXTENDED-RELEASE | 50 MG | TABLET (EXTENDED-RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02415577 |
| NUCYNTA IR | 100 MG | TABLET (IMMEDIATE RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02378299 |
| NUCYNTA IR | 50 MG | TABLET (IMMEDIATE RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02378272 |
| NUCYNTA IR | 75 MG | TABLET (IMMEDIATE RELEASE) | ENDO OPERATIONS LTD. | MARKETED | DIN 02378280 |
| APO-TAPENTADOL | 100 MG | TABLET (IMMEDIATE RELEASE) | APOTEX INC | APPROVED | DIN 02471981 |
| APO-TAPENTADOL | 75 MG | TABLET (IMMEDIATE RELEASE) | APOTEX INC | APPROVED | DIN 02471973 |
Who else supplies TAPENTADOL worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. TAPENTADOL appears in 87 registered pack listings across 8 markets, published on 8 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
This product is approved by Health Canada but not yet marketed in Canada, so there is no Canadian supply to draw on today. Nexara can tell you whether it has been launched, and can look at supply from other markets where a Canadian pack is not required or where importation is permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.